Company Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a class of medicines, which engages intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform (EEV Platform), the Company is building a robust development portfolio of therapeutic candidates. Its first two drug candidates, ENTR-601-44 and VX-670, are in clinical trials. VX-670 for dystrophy type 1 (DM1) is designed to block the triplet repeats in the messenger RNA (mRNA). ENTR-601-44 is in a Phase I clinical trial. The Company also announced the selection of additional clinical candidates within its Duchenne franchise, ENTR-601-45 and ENTR-601-50.

Number of employees: 159